Evidence map›Paper›PMID 42797539›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Critical Quality Attribute Investigation and Analytical Method Establishment for Glyco-Site-Specific Anti-HER2 Bispecific ADC.

Xiaojuan Yu, Lele Wang, Weirong Cao, Yao Tang, Tao Tang, Yangwei Fu, Yalan Yang, Chuanfei Yu, Yan Li, Lan Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaojuan YuNational Institutes for Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing 102629, China.
Lele WangJiangsu Alphamab Biopharmaceuticals Co., Ltd., Suzhou 215125, China.
Weirong CaoCSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang 050035, China.
Yao TangNMPA Center for Innovation and Research in Regulatory Science, Sichuan Institute for Drug Control, SCMPA Key Laboratory for Quality Monitoring and Risk Assessment of Biological Products, Chengdu 611731, China.
Tao TangNMPA Center for Innovation and Research in Regulatory Science, Sichuan Institute for Drug Control, SCMPA Key Laboratory for Quality Monitoring and Risk Assessment of Biological Products, Chengdu 611731, China.
Yangwei FuJiangsu Alphamab Biopharmaceuticals Co., Ltd., Suzhou 215125, China.
Yalan YangNational Institutes for Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing 102629, China.
Chuanfei YuNational Institutes for Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing 102629, China.
Yan LiNMPA Center for Innovation and Research in Regulatory Science, Sichuan Institute for Drug Control, SCMPA Key Laboratory for Quality Monitoring and Risk Assessment of Biological Products, Chengdu 611731, China.
Lan WangNational Institutes for Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing 102629, China.

Funding

Innovative Drug Research and Development National Science and Technology Major Project 2026ZD1805800State Key Laboratory of Drug Regulatory Science Project 2025SKLDRS0318
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bispecific antibody–drug conjugatescritical quality attributesdual HER2 epitopesquality control

Identifiers

PMID42797539
PMCPMC13610955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.